Neuren Pharmaceuticals Limited (NEU.AX)
AUD 12.43
(-0.08%)
AUD 12.43
(-0.08%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 247.97 Million AUD | 473.12% |
| 2022 | 43.26 Million AUD | 8.02% |
| 2021 | 40.05 Million AUD | 60.53% |
| 2020 | 24.95 Million AUD | 73.21% |
| 2019 | 14.4 Million AUD | -45.93% |
| 2018 | 26.64 Million AUD | 48.47% |
| 2017 | 17.94 Million AUD | 188.95% |
| 2016 | 6.21 Million AUD | -63.26% |
| 2015 | 16.9 Million AUD | -23.53% |
| 2014 | 22.1 Million AUD | -16.31% |
| 2013 | 26.41 Million AUD | 211.41% |
| 2012 | 8.48 Million AUD | -23.84% |
| 2011 | 11.13 Million AUD | 94.79% |
| 2010 | 5.71 Million AUD | -44.41% |
| 2009 | 10.28 Million AUD | 20.37% |
| 2008 | 8.54 Million AUD | -41.42% |
| 2007 | 14.58 Million AUD | -25.29% |
| 2006 | 19.52 Million AUD | -44.54% |
| 2005 | 35.2 Million AUD | 171.6% |
| 2004 | 12.96 Million AUD | 0.0% |
| 2003 | - AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 228.15 Million AUD | 0.0% |
| 2023 Q4 | 247.97 Million AUD | 0.0% |
| 2023 Q2 | 97.52 Million AUD | 0.0% |
| 2023 FY | 247.97 Million AUD | 473.12% |
| 2022 Q2 | 34.59 Million AUD | 0.0% |
| 2022 Q4 | 43.26 Million AUD | 0.0% |
| 2022 FY | 43.26 Million AUD | 8.02% |
| 2021 FY | 40.05 Million AUD | 60.53% |
| 2021 Q4 | 40.05 Million AUD | 0.0% |
| 2021 Q2 | 18.99 Million AUD | 0.0% |
| 2020 Q2 | 9.69 Million AUD | 0.0% |
| 2020 FY | 24.95 Million AUD | 73.21% |
| 2020 Q4 | 24.95 Million AUD | 0.0% |
| 2019 Q2 | 18.09 Million AUD | 0.0% |
| 2019 FY | 14.4 Million AUD | -45.93% |
| 2019 Q4 | 14.4 Million AUD | 0.0% |
| 2018 Q2 | 18.81 Million AUD | 0.0% |
| 2018 Q4 | 26.64 Million AUD | 0.0% |
| 2018 FY | 26.64 Million AUD | 48.47% |
| 2017 Q4 | 17.94 Million AUD | 0.0% |
| 2017 Q2 | 1.54 Million AUD | 0.0% |
| 2017 FY | 17.94 Million AUD | 188.95% |
| 2016 Q4 | 6.21 Million AUD | 0.0% |
| 2016 FY | 6.21 Million AUD | -63.26% |
| 2016 Q2 | 9.22 Million AUD | 0.0% |
| 2015 Q4 | 16.9 Million AUD | 0.0% |
| 2015 FY | 16.9 Million AUD | -23.53% |
| 2015 Q2 | 18.72 Million AUD | 0.0% |
| 2014 FY | 22.1 Million AUD | -16.31% |
| 2014 Q2 | 23.67 Million AUD | 0.0% |
| 2014 Q4 | 22.1 Million AUD | 0.0% |
| 2013 Q2 | 6.93 Million AUD | 0.0% |
| 2013 FY | 26.41 Million AUD | 211.41% |
| 2013 Q4 | 26.41 Million AUD | 0.0% |
| 2012 FY | 8.48 Million AUD | -23.84% |
| 2012 Q4 | 8.48 Million AUD | 0.0% |
| 2011 Q4 | 11.13 Million AUD | 0.0% |
| 2011 FY | 11.13 Million AUD | 94.79% |
| 2010 Q4 | 5.71 Million AUD | 0.0% |
| 2010 FY | 5.71 Million AUD | -44.41% |
| 2009 FY | 10.28 Million AUD | 20.37% |
| 2009 Q4 | 10.28 Million AUD | 0.0% |
| 2008 Q4 | 8.54 Million AUD | 0.0% |
| 2008 FY | 8.54 Million AUD | -41.42% |
| 2007 Q4 | 14.58 Million AUD | 0.0% |
| 2007 FY | 14.58 Million AUD | -25.29% |
| 2006 FY | 19.52 Million AUD | -44.54% |
| 2006 Q4 | 19.52 Million AUD | 0.0% |
| 2005 Q4 | 35.2 Million AUD | 0.0% |
| 2005 FY | 35.2 Million AUD | 171.6% |
| 2004 FY | 12.96 Million AUD | 0.0% |
| 2003 FY | - AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AdAlta Limited | 5.57 Million AUD | -4349.488% |
| Acrux Limited | 8.96 Million AUD | -2666.596% |
| Amplia Therapeutics Limited | 14.84 Million AUD | -1570.382% |
| Biome Australia Limited | 8.27 Million AUD | -2895.968% |
| BTC Health Limited | 5.14 Million AUD | -4716.067% |
| Chimeric Therapeutics Limited | 15.27 Million AUD | -1523.568% |
| CSL Limited | 56.93 Billion AUD | 99.564% |
| Clarity Pharmaceuticals Ltd | 154.62 Million AUD | -60.364% |
| Clinuvel Pharmaceuticals Limited | 231.12 Million AUD | -7.289% |
| Noxopharm Limited | 6.78 Million AUD | -3555.349% |
| PharmAust Limited | 11.12 Million AUD | -2128.974% |
| Proteomics International Laboratories Limited | 10.87 Million AUD | -2180.16% |
| Prescient Therapeutics Limited | 20.39 Million AUD | -1115.965% |
| PYC Therapeutics Limited | 91.23 Million AUD | -171.781% |
| Race Oncology Limited | 20.22 Million AUD | -1125.84% |
| Starpharma Holdings Limited | 36.81 Million AUD | -573.575% |
| EZZ Life Science Holdings Limited | 25.55 Million AUD | -870.453% |
| Botanix Pharmaceuticals Limited | 112.46 Million AUD | -120.487% |
| Memphasys Limited | 12.43 Million AUD | -1894.908% |
| Nyrada Inc. | 5.9 Million AUD | -4097.714% |
| Anatara Lifesciences Ltd | 1.67 Million AUD | -14735.87% |
| Telix Pharmaceuticals Limited | 398.3 Million AUD | 37.743% |
| Bio-Gene Technology Limited | 3.15 Million AUD | -7748.17% |
| Zelira Therapeutics Limited | 5.18 Million AUD | -4683.91% |
| Patrys Limited | 4.16 Million AUD | -5858.554% |
| Dimerix Limited | 32.07 Million AUD | -673.009% |
| Orthocell Limited | 26.61 Million AUD | -831.685% |
| Imugene Limited | 151.39 Million AUD | -63.787% |
| Cynata Therapeutics Limited | 8.38 Million AUD | -2856.145% |
| Immutep Limited | 147.44 Million AUD | -68.173% |
| Arovella Therapeutics Limited | 13.28 Million AUD | -1766.586% |
| Alterity Therapeutics Limited | 19.22 Million AUD | -1189.915% |
| Nanollose Limited | 241.95 Thousand AUD | -102387.694% |
| Invex Therapeutics Ltd | 6.12 Million AUD | -3951.764% |
| NeuroScientific Biopharmaceuticals Limited | 5.43 Million AUD | -4461.733% |
| Island Pharmaceuticals Limited | 2.56 Million AUD | -9569.441% |
| Biotron Limited | 493.47 Thousand AUD | -50149.658% |
| Radiopharm Theranostics Limited | 72.03 Million AUD | -244.229% |
| Tissue Repair Ltd | 19.38 Million AUD | -1178.883% |
| AnteoTech Limited | 9.38 Million AUD | -2543.271% |
| Hexima Limited | 2.26 Million AUD | -10828.584% |
| Paradigm Biopharmaceuticals Limited | 27.39 Million AUD | -805.316% |
| Recce Pharmaceuticals Ltd | 6.36 Million AUD | -3793.015% |
| Avecho Biotechnology Limited | 7.31 Million AUD | -3287.888% |
| Actinogen Medical Limited | 21.31 Million AUD | -1063.53% |
| Immuron Limited | 15.54 Million AUD | -1494.666% |
| Argenica Therapeutics Limited | 16.37 Million AUD | -1414.084% |